# Corcept Therapeutics 表示計劃重新提交其新藥申請至 FDA。

*biotech · news · 2026-05-27 · MarketScreener*

## Key points

- Corcept Therapeutics 將重新提交其治療庫欣氏症的藥物 relacorilant 的新藥申請。
- FDA 先前要求在考慮批准前提供更多 relacorilant 疗效證據。
- Corcept 根據 FDA 要求對新藥申請數據進行了額外分析。
- 公司計劃在分析結果正面後的數週內重新提交新藥申請。

By Connor Hart Corcept Therapeutics said it plans to resubmit its new drug application, or NDA, to the Food and Drug Administration for its treatment for hypercortisolism, also known as Cushing's Syndrome. The resubmission comes after the FDA in December said it required more evidence of effectiveness to support the application of the drug, called relacorilant. "Following issuance of its complete response letter, the FDA asked us to conduct additional analyses of our NDA data," Corcept Chief Executive Joseph Belanoff said Wednesday. "Based on the positive outcome of those analyses and the productive tenor of our discussions, we plan to resubmit our NDA in the coming weeks." He added that Corcept has appreciated the FDA's continued engagement throughout the process. Shares climbed 6%, to $64, in premarket trading. Write to Connor Hart at connor.hart@wsj.com (END) Dow Jones Newswires 05-27-26 0858ET

**Companies:** Corcept Therapeutics
**Countries:** United States

[Read the full story on MarketScreener](https://www.marketscreener.com/news/corcept-plans-to-resubmit-cushing-s-syndrome-drug-application-to-fda-ce7f5ad3d88af22c)

---

Canonical: https://newsio.io/zh-TW/n/1c316e10-41d4-4f9b-9ab8-d43cc5a6be4c/corcept-therapeutics-fda-fda
Summarized by Newsio from MarketScreener. https://newsio.io/how-it-works